Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Everolimus in Plexiform Neurofibromas Associated With Neurofibromatosis Type 1
2016-001563-36Phase 4
- Sponsor
- Novartis
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in plexiform neurofibroma (PN) and neurofibromatosis type 1 (NF1), sponsored by Novartis. Primary endpoint: Efficacy endpoints.
02
Drugs
everolimus
03
Conditions
plexiform neurofibroma (PN)neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on 2016-001563-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001563-36.